Annovis Bio

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Here is how Annovis Bio, Inc. (ANVS) and Aptose Biosciences (APTO) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?

BERWYN, Pa. , March 22, 2023 /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.

ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?

The consensus price target hints at a 152.9% upside potential for Annovis Bio, Inc. (ANVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 152.89%: Here's is How to Trade

The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries Annovis Currently has 50 Clinical Trial Sites Open in the United States BERWYN, Pa. , Feb. 8, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease ("PD").

Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 178.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?

BERWYN, Pa. , Feb. 1, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's and Parkinson's disease announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues.

Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

Strong enrollment in Phase 3 trial demonstrates continued execution Interim analysis expected in 2Q 2023 BERWYN, Pa. , Jan. 25, 2023  /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today provided a patient enrollment update for the Company's ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease ("PD").

ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE

BERWYN, Penn. , Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

The average of price targets set by Wall Street analysts indicates a potential upside of 251.4% in Annovis Bio, Inc. (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade

BERWYN, Penn. , Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments.

Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in New York City.

Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

BERWYN, Pa. , Oct. 11, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer's Disease.

Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

Annovis (ANVS) Gains on FDA Authorization for AD Study

Source: pathdoc / Shutterstock.com Annovis Bio (NYSE: ANVS ) stock is getting a boost on Thursday following news that the company will proceed with its Alzheimer's Disease clinical trial. FDA has signed off on the company's plans for a Phase/3 clinical trial of its Alzheimer's treatment.

Why Is Annovis Bio (ANVS) Stock Up 12% Today?

BERWYN, Pa. , Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026.

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

BERWYN, Pa. , Sept. 29, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City.

Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

BERWYN, Pa. , Sept. 13, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 (link), US11376238 (link), and US11382893 (link).

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

BERWYN, Pa. , Sept. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer Dr. Maria Maccecchini.

Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

BERWYN, Pa. , Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.

Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

BERWYN, Pa. , Aug. 24, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD) has been dosed.

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease

BERWYN, Pa. , Aug. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.

News for Annovis Bio Stock (ANVS)